| Human immunodeficiency virus I infection

Intelence vs Odefsey

Side-by-side clinical, coverage, and cost comparison for human immunodeficiency virus i infection.
Deep comparison between: Intelence vs Odefsey with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.
Safety signalsOdefsey has a higher rate of injection site reactions vs Intelence based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Odefsey but not Intelence, including UnitedHealthcare
Sign up to reveal the full AI analysis
Intelence
Odefsey
At A Glance
Oral
Twice daily
NNRTI
Oral
Once daily
NRTI + NNRTI combination
Indications
  • Human immunodeficiency virus I infection
  • Human immunodeficiency virus I infection
Dosing
Human immunodeficiency virus I infection 200 mg (one 200 mg tablet or two 100 mg tablets) orally twice daily following a meal
Human immunodeficiency virus I infection One tablet (emtricitabine 200 mg, rilpivirine 25 mg, tenofovir alafenamide 25 mg) orally once daily with a meal
Contraindications
—
  • Coadministration with carbamazepine
  • Coadministration with oxcarbazepine
  • Coadministration with phenobarbital
  • Coadministration with phenytoin
  • Coadministration with rifampin
  • Coadministration with rifapentine
  • Coadministration with dexamethasone (more than a single dose)
  • Coadministration with St. John's wort
  • Coadministration with proton pump inhibitors
Adverse Reactions
Most common (>=2%) Rash, peripheral neuropathy
Serious Severe skin reactions including Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme, drug hypersensitivity reactions including DRESS, hepatic failure, rhabdomyolysis
Postmarketing Fatal cases of toxic epidermal necrolysis and Stevens-Johnson syndrome, severe hypersensitivity reactions including DRESS and hepatic failure
Most common (>=2%) Headache, sleep disturbances
Serious Severe acute exacerbations of hepatitis B, skin and hypersensitivity reactions, hepatotoxicity, depressive disorders, new onset or worsening renal impairment, lactic acidosis/severe hepatomegaly with steatosis, immune reconstitution syndrome
Postmarketing Weight increased, severe skin and hypersensitivity reactions including DRESS, nephrotic syndrome, angioedema, urticaria, rash, acute renal failure, acute tubular necrosis, proximal renal tubulopathy, Fanconi syndrome
Pharmacology
Etravirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that binds directly to HIV-1 reverse transcriptase and blocks RNA-dependent and DNA-dependent DNA polymerase activities by disrupting the enzyme's catalytic site.
Odefsey is a fixed-dose combination of emtricitabine (an NRTI that inhibits HIV-1 reverse transcriptase by chain termination), rilpivirine (an NNRTI that non-competitively inhibits HIV-1 reverse transcriptase), and tenofovir alafenamide (a prodrug that is converted to tenofovir, an NRTI inhibiting HIV-1 reverse transcriptase by chain termination).
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Intelence
  • Covered on 5 commercial plans
  • PA (5/12) · Step Therapy (0/12) · Qty limit (11/12)
View full coverage details ›
Odefsey
  • Covered on 5 commercial plans
  • PA (5/12) · Step Therapy (0/12) · Qty limit (11/12)
View full coverage details ›
UnitedHealthcare
Intelence
  • Covered on 4 commercial plans
  • PA (0/8) · Step Therapy (0/8) · Qty limit (4/8)
View full coverage details ›
Odefsey
  • Covered on 4 commercial plans
  • PA (0/8) · Step Therapy (0/8) · Qty limit (8/8)
View full coverage details ›
Humana
Intelence
  • Covered on 0 commercial plans
  • PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
View full coverage details ›
Odefsey
  • Covered on 0 commercial plans
  • PA (0/3) · Step Therapy (0/3) · Qty limit (3/3)
View full coverage details ›
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableGood Days: HIV, AIDS Treatment & Prevention
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
$0
Gilead Advancing Access Patient Assistance Program/Medication Assistance Program (PAP/MAP)
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
  • Verify eligibility with the payer.
  • Pull the right PA forms directly from the payer.
  • Submit, track & send live updates to your dashboard.
Utilize patient records to autofill forms with our AI in seconds.
Free to start · HIPAA compliant
Next Steps for Your Patient
IntelenceView full Intelence profile
OdefseyView full Odefsey profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.